Home/Pipeline/ORIC-533

ORIC-533

Multiple Myeloma

Phase 1bInferred Active

Key Facts

Indication

Multiple Myeloma

Phase

Phase 1b

Status

Inferred Active

Company

ORIC Pharmaceuticals

About ORIC Pharmaceuticals

ORIC Pharmaceuticals is a clinical-stage biotech with a mission to overcome therapeutic resistance in cancer, a primary cause of treatment failure. The company has successfully raised over $900 million, advanced four programs into clinical trials, and is progressing key assets like ORIC-114 and rinzimetostat (ORIC-944) in late-phase 1b/2 studies. Its strategy centers on a proprietary resistance platform to develop combination therapies that extend the efficacy of standard-of-care treatments, positioning it as a potential partner of choice in the oncology landscape.

View full company profile

Therapeutic Areas

Oncology

Other Multiple Myeloma Drugs

Drug	Company	Phase	Status
Tasquinimod	Active Biotech	Preclinical	Active (Academic Partnership)
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
Kyprolis® (carfilzomib)	Cleo Life Sciences	Approved	Supported late-stage development & NDA
inobrodib (CCS1477)	CellCentric	Phase 1/2	Active
ISB 2001	Ichnos Glenmark Innovation	Phase 1b	Active
In Vivo Cell Therapy	GigaMune	Pre-clinical	Active
Hemady	Dexcel Pharma USA	Approved	Commercial
AV-353	AVEO Oncology	Pre-clinical	Active
Sequesta™	ID4Pharma	Pre-clinical	Active
Myeloma Consortium	Criterium	Unknown	Active
GPRC5D x CD3 TCE	Integral Molecular	Preclinical	Available for License
RORA-Tscm CAR-T	RORABio	Pre-clinical	Active